NASDAQ:RETAReata Pharmaceuticals Stock Price, Forecast & News

$135.42

-4.91 (-3.50 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$134.01

Now: $135.42▼

$142.79

50-Day Range

$137.73

MA: $154.09▼

$167.32

52-Week Range

$70.00

Now: $135.42▼

$257.96

Volume432,378 shs

Average Volume357,665 shs

Market Capitalization$4.50 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.03

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc. has a strategic collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to develop and commercialize Bard for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.

Beat the Market (BTM) Rank^™

4.4 Analyst's Opinion

Consensus Rating
Reata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $257.38, Reata Pharmaceuticals has a potential upside of 90.1% from its current price of $135.42.
Amount of Analyst Coverage
Reata Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Reata Pharmaceuticals has received 314 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Reata Pharmaceuticals has received 283 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Reata Pharmaceuticals has received 52.60% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote “Outperform” if you believe RETA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Reata Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reata Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reata Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $287,940.00 in company stock.
Percentage Held by Insiders
Only 31.70% of the stock of Reata Pharmaceuticals is held by insiders.
Percentage Held by Institutions
67.33% of the stock of Reata Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Reata Pharmaceuticals are expected to decrease in the coming year, from ($8.47) to ($10.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reata Pharmaceuticals is -13.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reata Pharmaceuticals is -13.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reata Pharmaceuticals has a P/B Ratio of 17.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:RETA

Previous Symbol

CUSIPN/A

CIK1358762

Webwww.reatapharma.com

Phone972-865-2219

Debt

Debt-to-Equity Ratio0.68

Current Ratio3.25

Quick Ratio3.25

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$26.52 million

Price / Sales169.72

Cash FlowN/A

Price / Cash FlowN/A

Book Value$7.74 per share

Price / Book17.50

Profitability

EPS (Most Recent Fiscal Year)($9.54)

Net Income$-290,170,000.00

Net Margins-1,542.06%

Return on Equity-322.36%

Return on Assets-65.04%

Miscellaneous

Employees123

Outstanding Shares33,237,000

Market Cap$4.50 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

How has Reata Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RETA stock has decreased by 14.2% and is now trading at $135.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Reata Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Reata Pharmaceuticals.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Reata Pharmaceuticals.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals Inc (NASDAQ:RETA) issued its quarterly earnings data on Monday, May, 11th. The company reported ($1.47) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.98) by $0.51. The company earned $1.35 million during the quarter, compared to the consensus estimate of $1.28 million. Reata Pharmaceuticals had a negative net margin of 1,542.06% and a negative return on equity of 322.36%. The firm's quarterly revenue was down 82.6% compared to the same quarter last year. During the same period last year, the business posted ($0.98) earnings per share. View Reata Pharmaceuticals' earnings history.

What price target have analysts set for RETA?

8 brokerages have issued 12 month price targets for Reata Pharmaceuticals' stock. Their forecasts range from $130.00 to $348.00. On average, they anticipate Reata Pharmaceuticals' stock price to reach $257.38 in the next twelve months. This suggests a possible upside of 90.1% from the stock's current price. View analysts' price targets for Reata Pharmaceuticals.

Has Reata Pharmaceuticals been receiving favorable news coverage?

News headlines about RETA stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Reata Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutReata Pharmaceuticals.

Who are some of Reata Pharmaceuticals' key competitors?

Some companies that are related to Reata Pharmaceuticals include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Sarepta Therapeutics (SRPT), Catalent (CTLT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Mylan (MYL), Dr.Reddy's Laboratories (RDY) and Ionis Pharmaceuticals (IONS). View all competitors.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), First Financial Bankshares (FFIN), Precision Drilling (PDS), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Archrock (AROC), Targa Resources (TRGP), Gilead Sciences (GILD) and Sangamo Therapeutics (SGMO).

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:

Mr. J. Warren Huff, Chairman, CEO & Pres (Age 65)
Dr. Colin J. Meyer, Chief Medical Officer & Exec. VP of Product Devel. (Age 40)
Dr. Keith W. Ward, Consultant (Age 49)
Mr. Jason D. Wilson, CFO & Exec. VP of Strategy (Age 49)
Ms. Elaine Castellanos, VP of Fin. & Accounting

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.09%), BlackRock Inc. (6.39%), Franklin Resources Inc. (3.62%), Duquesne Family Office LLC (1.60%), State Street Corp (1.56%) and Geode Capital Management LLC (1.10%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View institutional ownership trends for Reata Pharmaceuticals.

Which institutional investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Federated Hermes Inc., Franklin Resources Inc., Deutsche Bank AG, Osborn Williams & Donohoe LLC, Ghost Tree Capital LLC, and First Trust Advisors LP. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Warren Huff, and Jason Douglas Wilson. View insider buying and selling activity for Reata Pharmaceuticals.

Which institutional investors are buying Reata Pharmaceuticals stock?

RETA stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, TimesSquare Capital Management LLC, Pictet Asset Management Ltd., Duquesne Family Office LLC, Morgan Stanley, Two Sigma Investments LP, Geode Capital Management LLC, and Castleark Management LLC. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass, and James W Traweek Jr. View insider buying and selling activity for Reata Pharmaceuticals.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $135.42.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $4.50 billion and generates $26.52 million in revenue each year. The company earns $-290,170,000.00 in net income (profit) each year or ($9.54) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at 972-865-2219 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff